key: cord-0965267-4utvitqo
authors: Varma, Ankur; Kosuri, Satyajit; Ustun, Celalettin; Ibrahim, Uroosa; Moreira, Jonathan; Bishop, Michael R.; Nathan, Sunita; Mehta, Jayesh; Moncayo, Daniel; Heng, Joseph; Osman, Keren; Adekola, Kehinde U. A.
title: COVID-19 infection in hematopoietic cell transplantation: age, time from transplant and steroids matter
date: 2020-08-14
journal: Leukemia
DOI: 10.1038/s41375-020-01019-x
sha: fbb7f1d4c1beda5bd54b4c2480e5cf0b1ac27673
doc_id: 965267
cord_uid: 4utvitqo

nan

majority of patients were Caucasian males. Eleven patients (32%) were obese (BMI ≥ 30) and 20 (59%) had a history of smoking. Hypertension (N = 15, 44%) and diabetes (N = 13, 38%) were the most common comorbidities among all patients. Acute leukemia (N = 16, 47%), followed by multiple myeloma (N = 9, 26%) and lymphoma (N = 6, 18%) were the most common diagnoses. Peripheral blood (N = 30, 88%) was the stem cell source for the majority of them and most of the patients received myeloablative conditioning (N = 21, 62%).

The median time after HCT at which a COVID-19 infection occurred was 17.4 months for all patients; 18.9 months in the alloHCT and 13.2 months in the autoHCT recipients. Nine patients (26%) had active acute or chronic graft-versus-host disease (GVHD) at the time of COVID-19; 15 (44%) were on immunosuppressive drugs (ISP). Eleven (32%) patients were on steroids; ten (50%) in alloHCT (nine for GVHD, one for adrenal insufficiency), and one (7%) in autoHCT for relapse. The most common COVID-19 presenting symptom was fever (N = 25, 74%), followed by cough (N = 24, 71%) and dyspnea (N = 20, 59%) (Table 1) . Lymphopenia (N = 12/30, 40%), anemia (N = 18/30, 60%) and thrombocytopenia (N = 11/30, 37%) were common. D-dimer was elevated in 11/19 patients (58%); 10/13 alloHCT patients (77%) and 1/6 (17%) autoHCT patients. Chest radiography obtained in 28 patients showed that bilateral infiltrates (N = 21, 75%) was the most common abnormality.

Twenty patients (59%) had mild/moderate and 14 (41%) had severe COVID-19 at presentation. Twenty-five of 34 patients (74%) [alloHCT N = 14, 41%; autoHCT N = 11, 32%] were hospitalized for COVID-19 ( Table 2 ). The median duration of hospitalization was 8 days (range, 2-50 days). Eleven patients (32%) [alloHCT N = 8, 24%; autoHCT N = 3, 9%] were transferred to the medical intensive care unit (MICU). Eight of these patients (73%) were intubated [alloHCT group N = 6, autoHCT group N = 2], These authors contributed equally: Ankur Varma, Celalettin Ustun Table 1 ) associated with MICU admission and mortality, we found that age had a definitive impact on outcomes ( Supplementary  Fig. 4) . For the entire cohort, patients <40 years avoided MICU transfer or death. AutoHCT recipients <60 years also avoided these outcomes, however, all allo-HCT recipients >60 years (n = 3) requiring MICU transfer died. Interestingly, being underweight (defined as BMI ≤ 20) rather than obesity was associated with a higher rate of MICU transfer. ISP use post alloHCT was not associated with poorer outcomes. Being on steroids at diagnosis of COVID-19 was significantly associated with an increased rate of MICU admission and mortality in the entire cohort (Supplementary 5 ). There was a trend toward increased mortality for the patients who had active GVHD at COVID-19 diagnosis (p = 0.09) (Supplementary Fig. 6 ). Patients with COVID-19 within the first year of alloHCT had poorer survival than that after the first year (0% vs 87%, respectively. p = 0.007). Patients with hemoglobin <10 g/dL or platelet count <150 (×10 9 /L) had significantly increased mortality ( Supplementary Figs. 7 and 8) . Other factors associated with poor outcomes included a higher LDH, ferritin, and lymphopenia at COVID-19 diagnosis.

In conclusion, our study demonstrated that HCT recipients are at an increased risk of mortality compared to the general population [7] . Older age, being on steroids at diagnosis of COVID-19, and COVID-19 infection within 1 year of HCT, but not ISP use was associated with poor outcomes. Whether the steroid use by itself or comorbid conditions requiring steroid treatment is associated with inferior clinical outcomes deserves further investigation. Based upon our data, tapering or discontinuing ISP drugs in the setting of COVID-19 is not warranted.

Author contributions AV and CU: conceiving the idea, data collection, data analysis, literature search, writing and editing the manuscript. JH, UI, JM, SN, JM, DM, SK, KO, MB, KA: data collection, data analysis, literature search, writing and editing the manuscript.

Conflict of interest The authors declare that they have no conflict of interest.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

COVID-19 in persons with haematological cancers

Response to "COVID-19 in persons with haematological cancers

Multiple myeloma and COVID-19

Clinical characteristics and outcome of SARS-CoV-2-infected patients with haematological diseases: a retrospective case study in four hospitals in Italy, Spain and the Netherlands

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China

Real estimates of mortality following COVID-19 infection